Pregabalin Capsule
Product Images NDC 71610-931

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0931 30)

Pregabalin 25 mg capsule label by Aphena Pharma Solutions - Tennessee, LLC, displaying product name, strength, and quantity of 30 capsules. The label shows storage instructions to keep between 20-25°C, a medication guide advisory, manufacturer details in Apopka, NY, and packaging location in Cookeville, TN. It includes NDC 71610-931-30 and various barcodes.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin showing its molecular arrangement including the carboxylic acid and amine groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day with placebo, illustrating varying degrees of patient improvement by dose.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The graph illustrates efficacy trends of the treatment and placebo over a range of percent improvement values.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percent of patients improved based on percent improvement in pain from baseline. The chart compares four groups: Pregabalin 300 mg two times a day, Pregabalin 150 mg two times a day, Pregabalin 75 mg two times a day, and a placebo. Percent improvement in pain is on the x-axis, ranging from greater than 0 to 100%, and percent of patients improved is on the y-axis, ranging from 0 to 100%.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with lines indicating patient improvement across different pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing the relationship between pain improvement percentages and patient improvement rates.*

FDA Label Image

Figure 6 (Pregabalin 07)

This chart presents responder rates (%) comparing placebo and different doses of Pregabalin (100 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) across two clinical studies labeled Study E1 and Study E3. The x-axis shows dose groups including placebo, and the y-axis shows responder rate percentage. Sample sizes for each group are listed below the x-axis. The chart highlights statistically significant differences versus placebo.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting the seizure reduction as median percentage change from baseline against dose (mg/day) for four studies labeled Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID. The graph shows increasing seizure reduction with higher doses, with significant p-values noted at various points. Dose zero corresponds to placebo.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar chart showing responder rates (%) for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day dose (29.1%, N=103), and 10 mg/kg/day dose (40.6%, N=96). The vertical axis represents responder rate percentages from 0 to 60%, with each bar labeled by percentage and sample size below the horizontal axis.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph depicting percent improvement in pain from baseline on the X-axis and percent of patients improved on the Y-axis. Four lines represent different groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, showing trends of patient improvement percentages across these doses.*

FDA Label Image

Figure 10 (Pregabalin 11)

A line graph comparing the estimated percentage of subjects without LTR (Loss to Response) over 180 days between Pregabalin and placebo groups. The x-axis represents days, while the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Pregabalin shows a higher percentage without LTR over time compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph comparing the percentage of subjects improved over a range of improvement percentages from baseline to week 12. The graph features two lines representing Pregabalin and placebo, with the y-axis labeled 'Percent of Subjects Improved' and the x-axis labeled 'Percent Improved from Baseline to Week 12 BOCF.' The solid line corresponds to Pregabalin, showing a higher improvement rate than the dashed placebo line across the graph.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line chart comparing the percentage of subjects improved by Pregabalin versus Placebo, plotted against the percent improved from baseline to Week 16 BOCF. The graph shows two lines: a solid line for Pregabalin and a dashed line for Placebo, illustrating higher improvement percentages with Pregabalin across most values.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.